390 related articles for article (PubMed ID: 23234586)
1. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Roke Y; Buitelaar JK; Boot AM; Tenback D; van Harten PN
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):432-9. PubMed ID: 23234586
[TBL] [Abstract][Full Text] [Related]
2. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment.
Roke Y; van Harten PN; Buitelaar JK; Tenback DE; Quekel LG; de Rijke YB; Boot AM
Eur J Endocrinol; 2012 Dec; 167(6):855-63. PubMed ID: 23011870
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-induced hyperprolactinemia and testosterone levels in boys.
Roke Y; van Harten PN; Buitelaar JK; Tenback DE; de Rijke YB; Boot AM
Horm Res Paediatr; 2012; 77(4):235-40. PubMed ID: 22538969
[TBL] [Abstract][Full Text] [Related]
5. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
Masi G; Cosenza A; Mucci M
J Child Adolesc Psychopharmacol; 2001; 11(4):389-94. PubMed ID: 11838821
[TBL] [Abstract][Full Text] [Related]
6. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects.
Roke Y; van Harten PN; Boot AM; Buitelaar JK
J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):403-14. PubMed ID: 19702492
[TBL] [Abstract][Full Text] [Related]
8. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
Hellings JA; Zarcone JR; Valdovinos MG; Reese RM; Gaughan E; Schroeder SR
J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):885-92. PubMed ID: 16379508
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
10. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
Haas M; Karcher K; Pandina GJ
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643
[TBL] [Abstract][Full Text] [Related]
11. [Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].
Haefliger T; Bonsack C
Encephale; 2006; 32(1 Pt 1):97-105. PubMed ID: 16633296
[TBL] [Abstract][Full Text] [Related]
12. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
Park YM; Lee SH; Lee BH; Lee KY; Lee KS; Kang SG; Lee HY; Kim W
Psychiatry Res; 2016 May; 239():184-9. PubMed ID: 27010188
[TBL] [Abstract][Full Text] [Related]
13. Prolactin Levels During Long-Term Risperidone Treatment in Children and Adolescents: a reanalysis of data.
Findling RL; Daneman D
J Clin Psychiatry; 2016 Feb; 77(2):e155-70. PubMed ID: 26930529
[No Abstract] [Full Text] [Related]
14. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Kopecek M; Bares M; Horacek J; Mohr P
Neuro Endocrinol Lett; 2006 Dec; 27(6):803-6. PubMed ID: 17187006
[TBL] [Abstract][Full Text] [Related]
15. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.
Kinon BJ; Gilmore JA; Liu H; Halbreich UM
Psychoneuroendocrinology; 2003 Apr; 28 Suppl 2():55-68. PubMed ID: 12650681
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and safety profile of risperidone in a sample of children and adolescents.
Margari L; Matera E; Craig F; Petruzzelli MG; Palmieri VO; Pastore A; Margari F
Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
[TBL] [Abstract][Full Text] [Related]
18. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Calarge CA; Miller del D
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):163-9. PubMed ID: 21486167
[TBL] [Abstract][Full Text] [Related]
19. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
Calarge CA; Ellingrod VL; Acion L; Miller DD; Moline J; Tansey MJ; Schlechte JA
Pharmacogenet Genomics; 2009 May; 19(5):373-82. PubMed ID: 19339912
[TBL] [Abstract][Full Text] [Related]
20. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
Kinon BJ; Ahl J; Liu-Seifert H; Maguire GA
Psychoneuroendocrinology; 2006 Jun; 31(5):577-88. PubMed ID: 16488084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
